IFW

Services on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature

And Deposit: 47906

ean C. Baker, Esq., Reg. No. 35,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Joseph F. Poduslo, et al.

Serial No.:

10/775,562

Filed:

February 10, 2004

For:

AMINO ACID COMPOSITION WITH INCREASED BLOOD

BRAIN BARRIER PERMEABILITY

Group Art Unit:

1616

Examiner:

--

Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, Applicants in the above-identified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

Other Documents

- J.F. Poduslo, et al., "Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-enhanced Magnetic Resonance Imaging," Neurobiol. Dis. 11:315-329, 2002.
- J.S. Poduslo, et al., "Design and Chemical Synthesis of a Magnetic Resonance Contrast Agent with Enhanced *In Vitro* Binding, High Blood-Brain Barrier Permeability, and *In Vivo* Targeting to Alzheimer's Disease Amyloid Plaques," Biochemistry 43:6064-6075, 2004.

T.M. Wengenack, et al., "Targeting Alzheimer Amyloid Plaques *In Vivo*," Nat. Biotech. 18:868-872, 2000.

The enclosed documents are part of a PCT Search Report that issued in a related PCT application. Applicants state that each item of the information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Information Disclosure Statement.

No fees are believed necessary to enter this statement. However, if any fees are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Joseph F. Poduslo, et al.

April <u>29</u>, 2005

Jean C. Baker

Reg. No. 35,433

Quarles & Brady LLP

411 East Wisconsin Avenue Milwaukee, WI 53202-4497

(414) 277-5709



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/775,562 Filing Date February 10, 2004 INFORMATION DISCLOSURE First Named Inventor Joseph F. Poduslo STATEMENT BY APPLICANT Art Unit 1616 (Use as many sheets as necessary) Examiner Name Attorney Docket Number 630666.00028 Sheet

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
		Number-Kind Code ^{2 (# known)}			Figures Appear		
		US-					
		US-					
	<u> </u>	US-					
		US-					
		US-					
		US-					
		US-					
		US-		**			
		US-					
		US-					
		US-			-		
		US-					
		US-					
		US-					
		US-			•		
		US-					
		US-					
	<u> </u>	US-					
	 	US-	-				

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶		
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)						
	<u> </u>			***		L		
	-					_		
						H		
	 					-		
	<u> </u>					H		

Examiner	Date	
Signature	Considered	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known			
Substitu	te 10/10/11/1449/F10			Application Number	10/775,562		
INF	ORMATION	DIS	CLOSURE	Filing Date	February 10, 2004		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Joseph F. Poduslo		
	//	-4		Art Unit	1616		
(Use as many sheets as necessary)			ecessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	630666.00028		

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		J.F. Poduslo, et al., "Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-enhanced Magnetic Resonance Imaging," Neurobiol. Dis. 11:315-329, 2002.	
		J.F. Poduslo, et al., "Design and Chemical Synthesis of a Magnetic Resonance Contrast Agent with Enhanced In Vitro Binding, High Blood-Brain Barrier Permeability, and In Vivo Targeting to Alzheimer's Disease Amyloid Plagues, "Biochemistry	
		T.M. Wengenack, et al., "Targeting Alzheimer Amyloid Plaques In Vivo," Nat. Biotech. 18:868-872, 2000.	
•			

Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.